Lexicon Pharmaceuticals | LXRX - Заемный капитал





Заемный капитал Изменить Дата
Abbott USD 29.64B 19.74B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 24.75M 11.64M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 47.86B 8.49B 2026-06
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Illumina USD 1.49B 1000K 2026-06
Insmed USD 543.51M 1.3M 2026-06
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 37.34B 183M 2026-06
Lexicon Pharmaceuticals USD 49.68M 276K 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
MannKind USD 545.13M 2.93M 2026-06
Merck USD 51.08B 4.41B 2026-06
Moderna USD 597M 6M 2026-06
Novartis USD 37.49B 42M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Puma Biotechnology USD 10.87M 222K 2025-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Thermo Fisher Scientific USD 39.18B 890M 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12